Intravaginal estrogen
Intravaginal estrogen has been studied in 1 paper since 2024: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Aug 1, 2024: “Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-Analysis”.
1 paper studies it5 findingsUpdated
See all 1 papers on intravaginal estrogen
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Patients using estrogen showed a significant increase in superficial cells (mean differences [MD]: 19.28; 95% confidence intervals [CI]: 13.40 to 25.16; I2 = 90%; P < 0.00001)”
None of its findings points the other way.
- 1 lab in 1 country
Studies in people
1 study gave intravaginal estrogen to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases superficial cellsMD 19.28 (95% CI 13.40 to 25.16) down: Decreases vaginal pHMD -0.94 (95% CI -1.05 to -0.84) down: Decreases dyspareuniaMD -0.52 (95% CI -0.63 to -0.41) | Review of trials | 4,723 people pooledWomenpostmenopausalPostmenopausal women | Journal of menopausal medicine, Aug 1, 2024 |
What did studies of intravaginal estrogen find?
5Studies of intravaginal estrogen measured 5 outcomes; the most studied are adverse events (1 study), vaginal dryness (1) and dyspareunia (1).
Adverse events
no changein humans1RR 0.95
1 study
Adverse events
no changein humans1RR 0.95
Intravaginal estrogen showed no clear effect on adverse events in humans (compared with placebo) (RR 0.95 (95% CI 0.88 to 1.02)).
“Adverse events like vulvovaginal pruritis, mycotic infection, and urinary tract infection were reported, but the association was insignificant”
Human trialcompared with placebointravaginalvaginafemalesn = 4,723
Journal of menopausal medicine
Vaginal dryness
no changein humans1
1 study
Vaginal dryness
no changein humans1
Intravaginal estrogen showed no clear effect on vaginal dryness in humans (compared with placebo) (MD -0.04 (95% CI -0.18 to 0.11)).
“Estrogen did not significantly affect vaginal dryness (MD: -0.04; 95% CI: -0.18 to 0.11; I2 = 88%)”
Human trialcompared with placebointravaginalvaginafemalesn = 4,723
Journal of menopausal medicine
Dyspareunia
downin humans1
1 study
Dyspareunia
downin humans1
Intravaginal estrogen decreases dyspareunia in humans (compared with placebo) (MD -0.52 (95% CI -0.63 to -0.41)).
“Vaginal pH and dyspareunia significantly reduced in estrogen users (MD: -0.94; 95% CI: -1.05 to -0.84; I2 = 96%) and (MD: -0.52; 95% CI: -0.63 to -0.41; I2 = 99%)”
Human trialcompared with placebointravaginalvaginafemalesn = 4,723
Journal of menopausal medicine
Vaginal pH
downin humans1
1 study
Vaginal pH
downin humans1
Intravaginal estrogen decreases vaginal pH in humans (compared with placebo) (MD -0.94 (95% CI -1.05 to -0.84)).
“Vaginal pH and dyspareunia significantly reduced in estrogen users (MD: -0.94; 95% CI: -1.05 to -0.84; I2 = 96%)”
Human trialcompared with placebointravaginalvaginafemalesn = 4,723
Journal of menopausal medicine
Superficial cells
upin humans1
1 study
Superficial cells
upin humans1
Intravaginal estrogen increases superficial cells in humans (compared with placebo) (MD 19.28 (95% CI 13.40 to 25.16)).
“Patients using estrogen showed a significant increase in superficial cells (mean differences [MD]: 19.28; 95% confidence intervals [CI]: 13.40 to 25.16; I2 = 90%; P < 0.00001)”
Human trialcompared with placebointravaginalvaginafemalesn = 4,723
Journal of menopausal medicine